UNITED KINGDOM – Merk & Co’s checkpoint inhibitor Keytruda, which has been available for three years through the Cancer Drugs Fund (CDF), has now been approved for routine NHS use…
Read MoreNICE okays Merck’s Keytruda, giving it parity with Opdivo for adjuvant melanoma
